PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma

Rao, Liyun; Wang, Xiaoyan; Zong, Zhen; Chen, Zhifeng; Shi, Xiulin; Yi, Chang; Zhang, Xiangsong; Yang, Zhiyun

doi:10.1097/md.0000000000003750

Cited by 14 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SANT cannot be distinguished from other benign splenic tumors based on FDG-PET findings alone, but it can be a helpful tool to differentiate between certain malignant tumors such as lymphoma, metastases and angiosarcoma [ 28 29 30 ]. In addition, FDG-PET can exclude distant disease, typically absent in SANT ( Fig.…”

Section: Imaging Findingsmentioning

confidence: 99%

See 1 more Smart Citation

Sclerosing Angiomatoid Nodular Transformation of the Spleen: A Diagnostic Conundrum

Eede

Voorde

Vanhoenacker³

et al. 2022

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

A splenic lesion often represents a diagnostic challenge due to relative scarcity and the broad differential diagnosis. Sclerosing Angiomatoid Nodular Transformation (SANT) of the spleen is usually encountered only incidentally. Although benign, patients with SANT often receive splenectomy, due to its rarity, diagnostic uncertainty and sometimes intimidating imaging morphology and size. Imaging features on computed tomography, magnetic resonance and positron emission tomography have a high diagnostic value for SANT and help differentiate this entity from other splenic lesions. When the imaging parameters are matched with core needle biopsy tissue analysis, further watchful waiting can be recommended in order to avoid splenectomy.

show abstract

Section: Imaging Findingsmentioning

confidence: 99%

“…Fourteen authors performed FDG-PET in the work-up. Only a moderate uptake was noted with a median maximal standardized uptake value (SUVmax) of 2.8 MBq/g (range: 2.0–4.7 MBq/g), as opposed to malignant tumors with higher average values such as lymphoma that has a median SUVmax of 6.9MBq/g [ 28 ].…”

Section: Imaging Findingsmentioning

confidence: 99%

Sclerosing Angiomatoid Nodular Transformation of the Spleen: A Diagnostic Conundrum

Eede

Voorde

Vanhoenacker³

et al. 2022

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

show abstract

“…For SLR, age, CRP, focus of infection, and glucose before FDG-PET/CT reached an adjusted R 2 of 0.19. Because only 19% of SLR could be explained by our included factors, it is likely that other inflammatory markers (such as growth factors and cytokines) also play an important explanatory role in FDG uptake of the spleen in patients with bacteremia [ 32 , 33 ]. It is known that cytokines play a role in upregulation of active glucose transporters (GLUT) in the plasma membrane of cells, which also increases FDG uptake of these cells [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia

Pijl

Kwee

Slart

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose To investigate which clinical factors and laboratory values are associated with high FDG uptake in the bone marrow and spleen on 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with bacteremia. Methods One hundred forty-five consecutive retrospective patients with bacteremia who underwent FDG-PET/CT between 2010 and 2017 were included. Mean standard uptake values (SUVmean) of FDG in bone marrow, liver, and spleen were measured. Bone marrow-to-liver SUV ratios (BLR) and spleen-to-liver SUV ratios (SLR) were calculated. Linear regression analyses were performed to examine the association of BLR and SLR with age, gender, hemoglobin, leukocyte count, platelets, glucose level, C-reactive protein (CRP), microorganism, days of antibiotic treatment before FDG-PET/CT, infection focus, use of immunosuppressive drugs, duration of hospital stay (after FDG-PET/CT), ICU admission, and mortality. Results C-reactive protein (p = 0.006), a cardiovascular or musculoskeletal focus of infection (p = 0.000 for both), and bacteremia caused by Gram-negative bacteria (p = 0.002) were independently and positively associated with BLR, while age (p = 0.000) and glucose level before FDG-PET/CT (p = 0.004) were independently and negatively associated with BLR. For SLR, CRP (p = 0.001) and a cardiovascular focus of infection (p = 0.020) were independently and positively associated with SLR, while age (p = 0.002) and glucose level before FDG-PET/CT (p = 0.016) were independently and negatively associated with SLR. Conclusion High FDG uptake in the bone marrow is associated with a higher inflammatory response and younger age in patients with bacteremia. In patients with high FDG uptake in the bone marrow, a cardiovascular or musculoskeletal focus of infection is more likely than other foci, and the infection is more often caused by Gram-negative species. High splenic FDG uptake is associated with a higher inflammatory response as well, and a cardiovascular focus of infection is also more likely in case of high splenic FDG uptake.

show abstract

“…Threshold segmentation: A binary voxel data set was computed based on a given SUV range (SUV >41% of SUVmax 15 , 16 , 17 ), where 1 represents the lesion voxel and 0 represents nonlesion voxel, and the resolution of the binary data set was consistent with the PET/CT voxel resolution.…”

Section: Methodsmentioning

confidence: 99%

Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy

Dang,

Li,

Shen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

IntroductionChimeric antigen receptor (CAR) T cell therapy has markedly improved the prognosis of patients with diffuse large B‐cell lymphoma (DLBCL). The relative positioning of tumor lesions in lymphoma varies among patients, manifesting as either aggregation (clumped together) or dissemination (spread throughout the body). Prognostic significance of factors indicating the relative positioning of tumor lesions in CAR T cell therapy remains underexplored. For aggregation, prior research proposed the tumor volume surface ratio (TVSR), linking it to prognosis in chemotherapy. Regarding dissemination, indicators such as disease stage or extranodal involvement, commonly used in clinical practice, have not demonstrated prognostic significance in CAR T cell therapy. This study aims to analyze current indicators of tumor aggregation or dissemination and introduce a novel indicator to assess the prognostic value of tumor lesions' relative positioning in DLBCL patients undergoing CAR T cell therapy.MethodsThis retrospective study included 42 patients receiving CAR T cell therapy. Lesion image information was obtained from the last PET/CT scan prior to CAR T cell infusion, including total metabolic tumor volume, total tumor surface, diameter of lymphoma masses, and the sites of tumor lesions. We evaluated TVSR and bulky disease as descriptors of tumor aggregation. We refined existing indicators, stage III&IV and >1 site extranodal involvement, to distill a new indicator, termed ‘extra stage’, to better represent tumor dissemination. The study examined the prognostic significance of tumor aggregation and dissemination.ResultsOur findings indicate that TVSR, while prognostically valuable in chemotherapy, lacks practical prognostic value in CAR T cell therapy. Conversely, bulky disease emerged as an optimal prognostic indicator of tumor aggregation. Both bulky disease and extra stage were associated with poor prognosis and exhibiting synergistic prognostic impact in CAR T cell therapy.ConclusionsOverall, the relative positioning of tumor lesions significantly influences the prognosis of patients with DLBCL receiving CAR T cell therapy. The ideal scenario involves tumors with minimal dissemination and no aggregation.

show abstract

PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma

Cited by 14 publications

References 31 publications

Sclerosing Angiomatoid Nodular Transformation of the Spleen: A Diagnostic Conundrum

Sclerosing Angiomatoid Nodular Transformation of the Spleen: A Diagnostic Conundrum

Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia

Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy

Contact Info

Product

Resources

About